SIS3, a novel specific inhibitor of Smad3, inhibits TGF- and activin signaling by suppressing Smad3 phosphorylation without affecting the MAPK/p38, ERK, or PI3-kinase signaling pathways. SIS3 also inhibits the myofibroblast differentiation of fibroblasts by TGF-1. SIS3 completely diminishes the constitutive phosphorylation of Smad3 as well as the up-regulated type I collagen expression in scleroderma fibroblasts, thus abolishes the ECM overexpression in the TGF-1-treated normal dermal fibroblasts and scleroderma fibroblasts in vitro
For research use only. We do not sell to patients.